Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals w...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2021.1991710 |
| _version_ | 1797673262685093888 |
|---|---|
| author | Areti Tychala Georgios Meletis Eugenia Katsimpourlia Ioanna Gkeka Rodoula Dimitriadou Eleni Sidiropoulou Lemonia Skoura |
| author_facet | Areti Tychala Georgios Meletis Eugenia Katsimpourlia Ioanna Gkeka Rodoula Dimitriadou Eleni Sidiropoulou Lemonia Skoura |
| author_sort | Areti Tychala |
| collection | DOAJ |
| description | Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals with high titers. Antibody levels were assessed by the Abbott SARS-CoV-2 IgG II Quant assay. The interferon-γ production of T-cells in response to SARS-CoV-2 antigens was determined using Qiagen’s QuantiFERON SARS-CoV-2 ELISA test. Our results showed that participants with high antibody levels presented adequate cellular response in all studied cases, whereas those with low antibody levels generally showed limited to almost absent cellular response five months post vaccination. |
| first_indexed | 2024-03-11T21:42:59Z |
| format | Article |
| id | doaj.art-b44d477d367042e58b18d54f35062f35 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:42:59Z |
| publishDate | 2021-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-b44d477d367042e58b18d54f35062f352023-09-26T12:51:26ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2021-12-0117125148514910.1080/21645515.2021.19917101991710Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral responseAreti Tychala0Georgios Meletis1Eugenia Katsimpourlia2Ioanna Gkeka3Rodoula Dimitriadou4Eleni Sidiropoulou5Lemonia Skoura6Ahepa University HospitalAhepa University HospitalGeneral Hospital G. PapanikolaouAhepa University HospitalAhepa University HospitalAhepa University HospitalAhepa University HospitalVaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals with high titers. Antibody levels were assessed by the Abbott SARS-CoV-2 IgG II Quant assay. The interferon-γ production of T-cells in response to SARS-CoV-2 antigens was determined using Qiagen’s QuantiFERON SARS-CoV-2 ELISA test. Our results showed that participants with high antibody levels presented adequate cellular response in all studied cases, whereas those with low antibody levels generally showed limited to almost absent cellular response five months post vaccination.http://dx.doi.org/10.1080/21645515.2021.1991710covid-19bnt162b2cell-mediated immunity |
| spellingShingle | Areti Tychala Georgios Meletis Eugenia Katsimpourlia Ioanna Gkeka Rodoula Dimitriadou Eleni Sidiropoulou Lemonia Skoura Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response Human Vaccines & Immunotherapeutics covid-19 bnt162b2 cell-mediated immunity |
| title | Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response |
| title_full | Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response |
| title_fullStr | Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response |
| title_full_unstemmed | Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response |
| title_short | Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response |
| title_sort | evaluation of the quantiferon sars cov 2 assay to assess cellular immunogenicity of the bnt162b2 mrna covid 19 vaccine in individuals with low and high humoral response |
| topic | covid-19 bnt162b2 cell-mediated immunity |
| url | http://dx.doi.org/10.1080/21645515.2021.1991710 |
| work_keys_str_mv | AT aretitychala evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT georgiosmeletis evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT eugeniakatsimpourlia evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT ioannagkeka evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT rodouladimitriadou evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT elenisidiropoulou evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse AT lemoniaskoura evaluationofthequantiferonsarscov2assaytoassesscellularimmunogenicityofthebnt162b2mrnacovid19vaccineinindividualswithlowandhighhumoralresponse |